1. This Administrative Arrangement aims to strengthen the cooperation and exchange of information between the United States Food and Drug Administration (FDA) and the Directorate-General for Health and Food Safety of the European Commission (DG SANTE) regarding trade in bivalve molluscan shellfish, including edible species of oysters, clams, cockles, mussels, and roe-on scallops, either shucked or in the shell, whole or in part. The procedures described in this Administrative Arrangement are intended to accord with applicable respective domestic legislation.

2. FDA and DG SANTE note that it is intended to commence trade regarding raw and processed bivalve molluscs harvested from Approved growing areas in the United States by participants in the U.S. National Sanitation Program (NSSP participants), initially from Massachusetts and Washington, which are officially listed by DG SANTE on the “List of third countries and territories from which imports of live, chilled, frozen or processed bivalve molluscs for human consumption are permitted” (EU List), and raw bivalve molluscs harvested from eligible Class A production areas in the European Union (EU), initially by the EU Member States of the Netherlands and Spain, which are officially listed by FDA on the U.S Interstate Certified Shellfish Shippers List (ICSSL).

3. In the context of handling the requests by NSSP participants to be added to the EU List:

3.1. FDA intends to submit to DG SANTE requests from NSSP participants seeking to be added to the EU List.

3.2. FDA intends to review the information referred to in points 3.3 and 3.4 and inform DG SANTE that, based on the information provided, NSSP participants seeking to be added to the EU List have applied relevant U.S. measures.

3.3. FDA normally intends to submit the following documents and information with the requests referred to in points 3.1 and 3.2, unless a NSSP participant is seeking to be listed using point 3.4:
   a) List of Approved growing areas;
   b) List of firmsprocessors harvesting product in those Approved growing areas;
   c) Most recent FDA audit of the NSSP participant’s implementation of the NSSP and any corrective actions taken after the audit;
   d) Most recent sanitary survey(s) for those Approved growing areas;

---

1 In the United States, “Approved growing area” under the NSSP means any site which supports or could support the propagation of shellstock by natural or artificial means where harvest for direct marketing is allowed.

2 In the United States, the safety of raw molluscan shellfish is controlled by the application of measures in the U.S. National Shellfish Sanitation Program (NSSP). The NSSP is implemented in the United States at the sub-national state level, referred to as “NSSP participants.”

3 In the European Union, “Class A production area” is an area categorized according to the level of faecal contamination where harvesting of live bivalve molluscs for direct human consumption is permitted.
e) Most recent inspection reports for firms operating in those Approved growing areas and, in case of non-compliance, corrective actions taken by firms after the inspections;
f) List of laboratories performing official regulatory analysis of raw molluscan shellfish samples and the most recent NSSP evaluation report for each lab, including any resulting corrective actions; and
g) Summary description of applicable U.S. mechanisms for implementing and enforcing FDA regulations, plus enforcement of additional measures, if any, applied to those growing areas/processors.

3.4. For NSSP participants seeking to ship raw shellfish harvested from an Approved growing area in another NSSP participant that is already on the EU List, documentation normally consists of:
  a) The most recent Plant and Shipping Element Program Evaluation Report; and
  b) The most recent inspection report for each shellfish processing firm seeking to be listed for export to the EU.

3.5. Without limiting the number of NSSP participants to be considered, DG SANTE intends to evaluate promptly the documents referred to in point 3.3 or 3.4 and notify FDA of the results of its evaluation.

3.6. Following a positive evaluation, DG SANTE intends to promptly initiate its administrative procedures relevant to the context of handling the requests by NSSP participants to be added to the EU List, without prejudging the final outcome of such procedures.

4. In the context of handling the requests from EU Member States to be added to the ICSSL:

4.1. DG SANTE intends to submit to the FDA requests from EU Member States to be added to the ICSSL.

4.2. DG SANTE intends to review the information referred to in point 4.3 and inform FDA that, based on the information provided, EU Member States seeking to be added to the ICSSL have applied relevant EU measures, including additional agreed measures.

4.3. DG SANTE normally intends to submit the following documents and information with the requests referred to in points 4.1 and 4.2:
  a) List of eligible Class A production areas;
  b) List of firms/processors harvesting product in those Class A production areas;
  c) Most recent EC audit of the EU Member State’s implementation of EU measures, additional measures referenced in point 4.2, and the corrective actions taken, if any, after the audit;
  d) Most recent sanitary survey(s) for those eligible Class A production areas;
  e) Most recent inspection reports for firms operating in those Class A production areas and, in case of non-compliance, the corrective actions taken, if any, after the inspection;
  f) List of laboratories performing official regulatory analysis of raw molluscan shellfish samples, and the most recent ISO 17025:2017 (or equivalent) audit report for each laboratory, including any resulting corrective actions; and
g) Summary description of EU Member State's mechanisms for implementing and enforcing: EU measures applied to raw bivalve molluscan shellfish; any additional national measures adopted by the EU Member State; and application of additional agreed measures referenced in point 4.2.

4.4. Without limiting the number of EU Member States to be considered, FDA intends to evaluate promptly the documents referred to in point 4.3 and notify DG SANTE of the results of its evaluation.

4.5. Following a positive evaluation, FDA intends to promptly initiate its administrative procedures relevant to the context of handling the requests by EU Member States to be added to the ICSSL, without prejudging the final outcome of such procedures.

5. Generally, DG SANTE and FDA each understand that an on-site audit is not required when evaluating requests referred to in point 3 from NSSP participants or point 4 from EU Member States, but each may determine that an on-site audit is necessary, including either during an evaluation or to ensure that a positive determination of equivalence is maintained.

6. DG SANTE and FDA each intend to promptly notify the other:
   a) of any listed Class A production area in the EU or Approved growing area in the United States that is reclassified;
   b) any food safety concern regarding bivalve molluscan shellfish exported to the other, including outbreaks, recalls, and foods that could cause acute or chronic deleterious human health consequences;
   c) of any product exported to the other that does not conform to the other's equivalence determination; and
   d) of any plan to adopt, modify or repeal a measure related to the production of bivalve molluscan shellfish.

7. DG SANTE and FDA each intend that for all non-public information exchanged between them is to be exchanged in accordance with the Confidentiality Commitments between them.

8. For the purpose of implementing this Administrative Arrangement:
   a) The contact point for DG SANTE is Unit D3, Bilateral International Relations.
   b) The contact point for the FDA is from the Center for Food Safety and Applied Nutrition.
   c) The specific contact details are set out in the Annex to the present Administrative Arrangement.
   d) FDA and DG SANTE should notify each other of any changes to the contact persons.

9. DG SANTE and FDA intend to review periodically the present Administrative Arrangement and may jointly revise it.

4 FDA-SANCO Confidentiality Commitment of June 2005
https://www.fda.gov/international-programs/confidentiality-commitments/dg-sanco-europe-fda-confidentiality-commitment
https://www.fda.gov/international-programs/confidentiality-commitments/fda-dg-sanco-europe-confidentiality-commitment
10. This Administrative Arrangement does not create any rights or obligations, nor does it constitute a legally binding agreement. DG SANTE and FDA intend to give each other six months’ notice of an intent to discontinue using this arrangement.

11. DG SANTE and FDA intend for this Administrative Arrangement to commence when signed by both DG SANTE and FDA.

Signed in duplicate in the English language.

For the Directorate-General for Health and Food Safety of the European Commission:

Anne Bucher
Director-General

For the U.S. Food and Drug Administration:

Anna K. Abram
Deputy Commissioner for Policy, Legislation and International Affairs

Place: Brussels
Date: July 31, 2020

Place: Silver Spring, MD
Date: July 21, 2020
### ANNEX

Specific contact point details

<table>
<thead>
<tr>
<th>EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY</th>
<th>UNITED STATES FOOD AND DRUG ADMINISTRATION CENTER FOR FOOD SAFETY AND APPLIED NUTRITION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Paolo Caricato</td>
<td>Ms. Melissa Abbott</td>
</tr>
<tr>
<td>Ms. Aikaterini Argiri</td>
<td></td>
</tr>
<tr>
<td>European Commission</td>
<td></td>
</tr>
<tr>
<td>DG Health and Food Safety</td>
<td></td>
</tr>
<tr>
<td>Rue Froissart 101, Brussels, 1049, Belgium</td>
<td></td>
</tr>
<tr>
<td>Telephone: (00322) 2993202, 2987448</td>
<td></td>
</tr>
<tr>
<td>e-mail: <a href="mailto:pablo.caricato@ec.europa.eu">pablo.caricato@ec.europa.eu</a></td>
<td></td>
</tr>
<tr>
<td><a href="mailto:aikaterini.argiri@ec.europa.eu">aikaterini.argiri@ec.europa.eu</a></td>
<td></td>
</tr>
<tr>
<td>U.S. Food and Drug Administration</td>
<td></td>
</tr>
<tr>
<td>Center for Food Safety and Applied Nutrition</td>
<td></td>
</tr>
<tr>
<td>5001 Campus Drive College Park, MD 20740</td>
<td></td>
</tr>
<tr>
<td>Telephone: 240-402-1401</td>
<td></td>
</tr>
<tr>
<td>Fax: 301-436-2601</td>
<td></td>
</tr>
<tr>
<td>e-mail: <a href="mailto:Melissa.Abbott@fda.hhs.gov">Melissa.Abbott@fda.hhs.gov</a></td>
<td></td>
</tr>
</tbody>
</table>
1. This Administrative Arrangement aims to strengthen the cooperation and exchange of information between the United States Food and Drug Administration (FDA) and the Directorate-General for Health and Food Safety of the European Commission (DG SANTE) regarding trade in bivalve molluscan shellfish, including edible species of oysters, clams, cockles, mussels, and roe-on scallops, either shucked or in the shell, whole or in part. The procedures described in this Administrative Arrangement are intended to accord with applicable respective domestic legislation.

2. FDA and DG SANTE note that it is intended to commence trade regarding raw and processed bivalve molluscs harvested from Approved growing areas¹ in the United States by participants in the U.S. National Sanitation Program (NSSP participants²), initially from Massachusetts and Washington, which are officially listed by DG SANTE on the “List of third countries and territories from which imports of live, chilled, frozen or processed bivalve molluscs for human consumption are permitted” (EU List), and raw bivalve molluscs harvested from eligible Class A production areas³ in the European Union (EU), initially by the EU Member States of the Netherlands and Spain, which are officially listed by FDA on the U.S Interstate Certified Shellfish Shippers List (ICSSL).

3. In the context of handling the requests by NSSP participants to be added to the EU List:

   3.1. FDA intends to submit to DG SANTE requests from NSSP participants seeking to be added to the EU List.

   3.2. FDA intends to review the information referred to in points 3.3 and 3.4 and inform DG SANTE that, based on the information provided, NSSP participants seeking to be added to the EU List have applied relevant U.S. measures.

   3.3. FDA normally intends to submit the following documents and information with the requests referred to in points 3.1 and 3.2, unless a NSSP participant is seeking to be listed using point 3.4:
   
   a) List of Approved growing areas;
   b) List of firms/processors harvesting product in those Approved growing areas;
   c) Most recent FDA audit of the NSSP participant’s implementation of the NSSP and any corrective actions taken after the audit;
   d) Most recent sanitary survey(s) for those Approved growing areas;

---

¹ In the United States, “Approved growing area” under the NSSP means any site which supports or could support the propagation of shellstock by natural or artificial means where harvest for direct marketing is allowed.

² In the United States, the safety of raw molluscan shellfish is controlled by the application of measures in the U.S. National Shellfish Sanitation Program (NSSP). The NSSP is implemented in the United States at the sub-national State level, referred to as “NSSP participants.”

³ In the European Union, “Class A production area” is an area categorized according to the level of faecal contamination where harvesting of live bivalve molluscs for direct human consumption is permitted.
e) Most recent inspection reports for firms operating in those Approved growing areas and, in case of non-compliance, corrective actions taken by firms after the inspections;
f) List of laboratories performing official regulatory analysis of raw molluscan shellfish samples and the most recent NSSP evaluation report for each lab, including any resulting corrective actions; and

g) Summary description of applicable U.S. mechanisms for implementing and enforcing FDA regulations, plus enforcement of additional measures, if any, applied to those growing areas/processors.

3.4. For NSSP participants seeking to ship raw shellfish harvested from an Approved growing area in another NSSP participant that is already on the EU List, documentation normally consists of:
   a) The most recent Plant and Shipping Element Program Evaluation Report; and
   b) The most recent inspection report for each shellfish processing firm seeking to be listed for export to the EU.

3.5. Without limiting the number of NSSP participants to be considered, DG SANTE intends to evaluate promptly the documents referred to in point 3.3 or 3.4 and notify FDA of the results of its evaluation.

3.6. Following a positive evaluation, DG SANTE intends to promptly initiate its administrative procedures relevant to the context of handling the requests by NSSP participants to be added to the EU List, without prejudging the final outcome of such procedures.

4. In the context of handling the requests from EU Member States to be added to the ICSSL:

4.1. DG SANTE intends to submit to the FDA requests from EU Member States to be added to the ICSSL.

4.2. DG SANTE intends to review the information referred to in point 4.3 and inform FDA that, based on the information provided, EU Member States seeking to be added to the ICSSL have applied relevant EU measures, including additional agreed measures.

4.3. DG SANTE normally intends to submit the following documents and information with the requests referred to in points 4.1 and 4.2:
   a) List of eligible Class A production areas;
   b) List of firms/processors harvesting product in those Class A production areas;
   c) Most recent EC audit of the EU Member State’s implementation of EU measures, additional measures referenced in point 4.2, and the corrective actions taken, if any, after the audit;
   d) Most recent sanitary survey(s) for those eligible Class A production areas;
   e) Most recent inspection reports for firms operating in those Class A production areas and, in case of non-compliance, the corrective actions taken, if any, after the inspection;
   f) List of laboratories performing official regulatory analysis of raw molluscan shellfish samples, and the most recent ISO 17025:2017 (or equivalent) audit report for each laboratory, including any resulting corrective actions; and
4.4. Without limiting the number of EU Member States to be considered, FDA intends to evaluate promptly the documents referred to in point 4.3 and notify DG SANTE of the results of its evaluation.

4.5. Following a positive evaluation, FDA intends to promptly initiate its administrative procedures relevant to the context of handling the requests by EU Member States to be added to the ICSSL, without prejudging the final outcome of such procedures.

5. Generally, DG SANTE and FDA each understand that an on-site audit is not required when evaluating requests referred to in point 3 from NSSP participants or point 4 from EU Member States, but each may determine that an on-site audit is necessary, including either during an evaluation or to ensure that a positive determination of equivalence is maintained.

6. DG SANTE and FDA each intend to promptly notify the other:
   a) of any listed Class A production area in the EU or Approved growing area in the United States that is reclassified;
   b) any food safety concern regarding bivalve molluscan shellfish exported to the other, including outbreaks, recalls, and foods that could cause acute or chronic deleterious human health consequences;
   c) of any product exported to the other that does not conform to the other’s equivalence determination; and
   d) of any plan to adopt, modify or repeal a measure related to the production of bivalve molluscan shellfish.

7. DG SANTE and FDA each intend that for all non-public information exchanged between them is to be exchanged in accordance with the Confidentiality Commitments\(^4\) between them.

8. For the purpose of implementing this Administrative Arrangement:
   a) The contact point for DG SANTE is Unit D3, Bilateral International Relations.
   b) The contact point for the FDA is from the Center for Food Safety and Applied Nutrition.
   c) The specific contact details are set out in the Annex to the present Administrative Arrangement.
   d) FDA and DG SANTE should notify each other of any changes to the contact persons.

9. DG SANTE and FDA intend to review periodically the present Administrative Arrangement and may jointly revise it.

---

\(^4\) FDA-SANCO Confidentiality Commitment of June 2005
https://www.fda.gov/international-programs/confidentiality-commitments/dg-sanco-europe-fda-confidentiality-commitment
https://www.fda.gov/international-programs/confidentiality-commitments/fda-dg-sanco-europe-confidentiality-commitment
10. This Administrative Arrangement does not create any rights or obligations, nor does it constitute a legally binding agreement. DG SANTE and FDA intend to give each other six months’ notice of an intent to discontinue using this arrangement.

11. DG SANTE and FDA intend for this Administrative Arrangement to commence when signed by both DG SANTE and FDA.

Signed in duplicate in the English language.

For the Directorate-General for Health and Food Safety of the European Commission: For the U.S. Food and Drug Administration:

_________________________________ ________________________________
Anne Bucher Mark Abdoo
Director-General Associate Commissioner for Global Policy and Strategy

Place: Brussels Place: Silver Spring, MD
Date: ___________________________ Date ___________________________
**ANNEX**

**Specific contact point details**

<table>
<thead>
<tr>
<th>EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY</th>
<th>UNITED STATES FOOD AND DRUG ADMINISTRATION CENTER FOR FOOD SAFETY AND APPLIED NUTRITION</th>
</tr>
</thead>
</table>
| Mr. Paolo Caricato  
Ms. Aikaterini Argiri | Ms. Melissa Abbott |
| European Commission  
DG Health and Food Safety  
Rue Froissart 101, Brussels, 1049, Belgium  
Telephone: (00322) 2993202, 2987448  
e-mail: paolo.caricato@ec.europa.eu  
aikaterini.argiri@ec.europa.eu | U.S. Food and Drug Administration  
Center for Food Safety and Applied Nutrition  
5001 Campus Drive College Park, MD 20740  
Telephone: 240-402-1401  
Fax: 301-436-2601  
e-mail: Melissa.Abbott@fda.hhs.gov |